title: Update on combinations of DAAs with and without pegylated-interferon and ribavirin: triple and quadruple therapy more than doubles SVR.
abstract: Monotherapy is an ineffective way to treat hepatitis C and it leads to rapid development of resistance. An increasing number of drugs are currently being developed for the treatment of hepatitis C. This allows combination strategies that can overcome the development of resistance and improve sustained virologic response rates. This article focuses on the 2 main strategies in development: quadruple combination therapies, including pegylated-interferon and triple/quadruple pegylated-interferon free combination therapies. If the first combinations are leading to extremely high sustained virologic responses, the second ones offer hope that the era of pegylated-interferon will end soon.
authors.affiliation: Division of Liver Diseases, Department of Medicine, Mount Sinai School of Medicine, New York, NY 10029, USA. valerie.martel-laferriere@mountsinai.org
authors.forename: Valérie
authors.initials: V
authors.lastname: Martel-Laferrière
authors.forename: Douglas T
authors.initials: DT
authors.lastname: Dieterich
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D016174:Hepacivirus / Q000201:enzymology / Q000235:genetics; D006526:Hepatitis C / Q000188:drug therapy*; D006801:Humans; D007372:Interferons / Q000627:therapeutic use; D010456:Peptides, Cyclic / Q000627:therapeutic use*; D010721:Phosphinic Acids / Q000627:therapeutic use*; D011092:Polyethylene Glycols / Q000627:therapeutic use; D011480:Protease Inhibitors / Q000627:therapeutic use*; D011804:Quinolines / Q000627:therapeutic use*; D012254:Ribavirin / Q000627:therapeutic use; D000069474:Sofosbuvir; D014542:Uridine Monophosphate / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D000998:Antiviral Agents; C571665:GS-9256; C573362:GS-9451; D010456:Peptides, Cyclic; D010721:Phosphinic Acids; D011480:Protease Inhibitors; D011804:Quinolines; D011092:Polyethylene Glycols; D012254:Ribavirin; D007372:Interferons; D014542:Uridine Monophosphate; D000069474:Sofosbuvir